Masoumeh Farahani Assistant Professor , Matineh Nirouei Doctor of Medicine , Somaye Moghadam Bachelor of Midwifery , Maryam Hashemnejad Assistant Professor , Banafsheh Mashak Assistant Professor , Tina Alinia Doctor of Medicine , Sahar Torabi Bachelor of Midwifery
{"title":"阴道使用地塞米松片提高未产孕妇宫颈Bishop评分的效果:一项随机临床试验","authors":"Masoumeh Farahani Assistant Professor , Matineh Nirouei Doctor of Medicine , Somaye Moghadam Bachelor of Midwifery , Maryam Hashemnejad Assistant Professor , Banafsheh Mashak Assistant Professor , Tina Alinia Doctor of Medicine , Sahar Torabi Bachelor of Midwifery","doi":"10.1016/j.curtheres.2023.100702","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Cervix ripening and labor induction are common interventions in obstetrics. For optimal maternal health, labor may be induced under certain situations to improve fetal survival outcomes. Labor induction of an unripe cervix can lead to complications; therefore, several approaches can facilitate the ripening process.</p></div><div><h3>Methods</h3><p>This randomized clinical trial was a triple-blind study that involved 84 pregnant nulliparous women enrolled between October 2019 and June 2021 in the labor ward of Kamali Hospital, Karaj, Iran. The pregnant women in the study underwent labor induction and were randomized into 2 groups: 1 group received vaginal dexamethasone and the other group was given a placebo.</p></div><div><h3>Results</h3><p>There was no significant difference between the groups regarding maternal age, demographic characteristics, and initial Bishop score. The median second Bishop score (6 hours after intervention) was 3.5 in dexamethasone recipients and 3 in placebo recipients (<em>P</em> = 0.48). The median labor latent phase duration was 4 hours in dexamethasone recipients and 5 hours in placebo recipients (<em>P</em> = 0.57).</p></div><div><h3>Conclusions</h3><p>This randomized clinical trial demonstrated that administering dexamethasone tablets vaginally did not significantly improve cervical Bishop scores. (<em>Curr Ther Res Clin Exp</em>. 2023; 84:XXX–XXX). ClinicalTrials.gov identifier: NCT05070468.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"98 ","pages":"Article 100702"},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124091/pdf/main.pdf","citationCount":"0","resultStr":"{\"title\":\"The Effect of Using Dexamethasone Tablets Vaginally for Improving Cervical Bishop Score in Nulliparous Pregnant Women: A Randomized Clinical Trial\",\"authors\":\"Masoumeh Farahani Assistant Professor , Matineh Nirouei Doctor of Medicine , Somaye Moghadam Bachelor of Midwifery , Maryam Hashemnejad Assistant Professor , Banafsheh Mashak Assistant Professor , Tina Alinia Doctor of Medicine , Sahar Torabi Bachelor of Midwifery\",\"doi\":\"10.1016/j.curtheres.2023.100702\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Cervix ripening and labor induction are common interventions in obstetrics. For optimal maternal health, labor may be induced under certain situations to improve fetal survival outcomes. Labor induction of an unripe cervix can lead to complications; therefore, several approaches can facilitate the ripening process.</p></div><div><h3>Methods</h3><p>This randomized clinical trial was a triple-blind study that involved 84 pregnant nulliparous women enrolled between October 2019 and June 2021 in the labor ward of Kamali Hospital, Karaj, Iran. The pregnant women in the study underwent labor induction and were randomized into 2 groups: 1 group received vaginal dexamethasone and the other group was given a placebo.</p></div><div><h3>Results</h3><p>There was no significant difference between the groups regarding maternal age, demographic characteristics, and initial Bishop score. The median second Bishop score (6 hours after intervention) was 3.5 in dexamethasone recipients and 3 in placebo recipients (<em>P</em> = 0.48). The median labor latent phase duration was 4 hours in dexamethasone recipients and 5 hours in placebo recipients (<em>P</em> = 0.57).</p></div><div><h3>Conclusions</h3><p>This randomized clinical trial demonstrated that administering dexamethasone tablets vaginally did not significantly improve cervical Bishop scores. (<em>Curr Ther Res Clin Exp</em>. 2023; 84:XXX–XXX). ClinicalTrials.gov identifier: NCT05070468.</p></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"98 \",\"pages\":\"Article 100702\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124091/pdf/main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X23000127\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景宫颈成熟和引产是产科常见的干预措施。为了获得最佳的产妇健康,可以在某些情况下引产,以提高胎儿的存活率。宫颈未成熟的引产会导致并发症;因此,几种方法可以促进成熟过程。方法这项随机临床试验是一项三盲研究,涉及2019年10月至2021年6月在伊朗卡拉杰Kamali医院分娩病房登记的84名未产妇。研究中的孕妇接受了引产,并被随机分为两组:一组接受阴道地塞米松治疗,另一组接受安慰剂治疗。结果两组在产妇年龄、人口学特征和初始Bishop评分方面无显著差异。地塞米松受试者的第二次Bishop评分中位数(干预后6小时)为3.5,安慰剂受试者为3(P = 地塞米松组的中位产程潜伏期为4小时,安慰剂组为5小时(P = 0.57)。结论本随机临床试验表明,阴道给药地塞米松片并不能显著改善宫颈Bishop评分。(Curr Ther Res Clin Exp.2023;84:XXX–XXX)。ClinicalTrials.gov标识符:NCT05070468。
The Effect of Using Dexamethasone Tablets Vaginally for Improving Cervical Bishop Score in Nulliparous Pregnant Women: A Randomized Clinical Trial
Background
Cervix ripening and labor induction are common interventions in obstetrics. For optimal maternal health, labor may be induced under certain situations to improve fetal survival outcomes. Labor induction of an unripe cervix can lead to complications; therefore, several approaches can facilitate the ripening process.
Methods
This randomized clinical trial was a triple-blind study that involved 84 pregnant nulliparous women enrolled between October 2019 and June 2021 in the labor ward of Kamali Hospital, Karaj, Iran. The pregnant women in the study underwent labor induction and were randomized into 2 groups: 1 group received vaginal dexamethasone and the other group was given a placebo.
Results
There was no significant difference between the groups regarding maternal age, demographic characteristics, and initial Bishop score. The median second Bishop score (6 hours after intervention) was 3.5 in dexamethasone recipients and 3 in placebo recipients (P = 0.48). The median labor latent phase duration was 4 hours in dexamethasone recipients and 5 hours in placebo recipients (P = 0.57).
Conclusions
This randomized clinical trial demonstrated that administering dexamethasone tablets vaginally did not significantly improve cervical Bishop scores. (Curr Ther Res Clin Exp. 2023; 84:XXX–XXX). ClinicalTrials.gov identifier: NCT05070468.
期刊介绍:
We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics.
CTR encourages and supports the submission of manuscripts describing:
• Interventions designed to understand or improve human health, disease treatment or disease prevention;
• Studies that focus on problems that are uncommon in resource-rich countries;
• Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing);
• Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English;
• Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.